Autonomous AI and patients: Safety, Efficacy, Equity

Dr. Michael D. Abramoff, MD, PhD, is a fellowship-trained retina specialist, computer scientist and entrepreneur. He is Founder and CEO of IDx, the first company ever to receive FDA clearance for an autonomous AI diagnostic system. In this capacity, as an expert on AI in healthcare, he has been invited to brief the US Congress, the White House and the Federal Trade Commission. He continues to treat patients with retinal disease and trains medical students, residents, and fellows, as well as engineering graduate students at the University of Iowa. Dr. Abramoff has published over 260 peer reviewed journal papers (h-index 58) on AI, image analysis, and retinal diseases, and many book chapters, that have been cited over 27,000 times. He is the inventor on 17 patents and 5 patent applications on AI, medical imaging and image analysis. In 2010, Dr. Abramoff?s research findings led him to found IDx, to bring to patients more affordable, more accessible, and higher quality healthcare. IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. The company is focused on developing clinically-aligned autonomous AI. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection. In 2018, IDx became the first company ever to receive FDA clearance for an autonomous AI diagnostic system. The system, called IDx-DR, detects diabetic retinopathy without requiring a physician to interpret the results.